title: Combinatorial Versus Individual Gene Pharmacogenomic Testing in Mental Health: A Perspective on Context and Implications on Clinical Utility.
abstract: Pharmacogenomic testing in mental health has not yet reached its full potential. An important reason for this involves differentiating individual gene testing (IGT) from a combinatorial pharmacogenomic (CPGx) approach. With IGT, any given gene reveals specific information that may, in turn, pertain to a smaller number of medications. CPGx approaches attempt to encompass more complete genomic information by combining moderate risk alleles and synergistically viewing the results from the perspective of the medication. This manuscript will discuss IGT and CPGx approaches to psychiatric pharmacogenomics and review the clinical validity, clinical utility, and economic parameters of both.
authors.affiliation: Assurex Health Inc., Mason, Ohio.
authors.forename: Joel G
authors.initials: JG
authors.lastname: Winner
authors.affiliation: Assurex Health Inc., Mason, Ohio.
authors.forename: Bryan
authors.initials: B
authors.lastname: Dechairo
mesh_terms: D005796:Genes / Q000235:genetics; D005820:Genetic Testing / Q000379:methods; D006801:Humans; D001523:Mental Disorders / Q000235:genetics*; D010597:Pharmacogenetics / Q000379:methods
keywords: clinical utility; clinical validity; combinatorial; economic outcomes; mental health; pharmacogenomics